ImmunoKey

Over 200,000 people die from ovarian cancer every year. At ImmunoKey, we’re building CAR T therapies designed to finally work against solid tumours, and we’re starting with ovarian cancer. Here is our approach. #CAR_TCellTherapy #ovariancancer

It's a privilege to have two distinguished experts join our SAB. I'm looking forward to working closely with them to help us deliver our CARKey technology to patients.

ImmunoKey Announces New Scientific Advisory Board Members We’re excited to welcome two world-renowned experts in T-cell immunotherapy, Professor Phil Darcy and Dr. David Gilham, to ImmunoKey’s Scientific Advisory Board. 🔬 Prof. Phil Darcy, Peter MacCallum Cancer Centre, led Australia’s first CAR-T trial and has published 200+ papers cited over 26,000 times. 🧬 Dr. David Gilham, former CSO at Celyad Oncology and University of Manchester academic, brings decades of experience translating CAR-T and allogeneic therapies to the clinic. With their guidance, we’re even better positioned to bring next-gen CAR T-cell therapies to patients with solid tumours. Read more here: https://lnkd.in/eb7iavM5 #CellTherapy #CAR_T #ImmunoOncology #BiotechNews #OvarianCancer #ImmunoKey #CancerResearch #TCellTherapy

📢 Access to our investor webinar recording 📢 Yesterday we held a webinar for interested investors, to introduce ImmunoKey’s senior team and share more about our pioneering CAR T-cell therapy platform. It was a great session, covering our technology, team experience and the large market opportunity. As well as, most importantly, how ImmunoKey can transform patient outcomes in solid cancers. The recording can be accessed on Vimeo: https://lnkd.in/et_eFJi9 As a reminder, we’re live on Crowdcube until next week, and you can become a shareholder from just £10.32 here: https://lnkd.in/esSDNAAV Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more: https://lnkd.in/d2pbNbb #BIOEurope #CellTherapy #ImmunoOncology #Startups #EIS #raisinginvestment #crowdfunding #OvarianCancer #CARKey #ImmunoKey

Invitation to our investor webinar We’re delighted to be live on the Crowdcube platform - thank you all for sharing in our journey, and to our early investors who’ve got our crowdfund off to a great start! We appreciate there is a lot for interested investors to learn and digest, so with that in mind, we’re hosting an investor webinar on Tuesday 6th January at 11 AM. We’ll be giving a breakdown of ImmunoKey, including its inception, the team behind it and our plans from 2026 through to exit. We’ll also be opening the floor to investors for a Q&A. You can register for your free spot via Zoom on this link : https://lnkd.in/ePcHe8hE In the meantime, if you have any questions at all please feel free to email directly at investors@immunokey.co.uk. Hope to see you there! Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more: https://lnkd.in/d2pbNbb #BIOEurope #CellTherapy #ImmunoOncology #Startups #EIS #raisinginvestment #crowdfunding #OvarianCancer #CARKey #ImmunoKey

📢 Open to new shareholders 📢 We’re delighted to announce that we’re live on @Crowdcube. We’re inviting shareholders to join us in pioneering our immune therapy platform to transform patient outcomes in solid cancers. We’re raising investment to support pre-clinical studies following the development of CARKey™, our CAR T-cell therapy platform. ✅Patent-filed design ✅Targets multiple antigens to give enhanced tumour coverage  ✅Safeguards healthy tissue from toxicity ✅Led by biotech experts who conducted the first CAR T-cell therapy trials in the UK ✅First focus is on ovarian cancer, where there is a high unmet need for effective treatments We warmly invite our network to view our pitch below to find out more. You can become a shareholder from just £10.32, supporting us in developing the keys to unlock cancer cures. https://lnkd.in/esSDNAAV Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more: https://lnkd.in/d2pbNbb #BIOEurope #CellTherapy #ImmunoOncology #Startups #EIS #raisinginvestment #crowdfunding #OvarianCancer #CARKey #ImmunoKey

We’re excited to announce that ImmunoKey has been accepted into the Creative Destruction Lab, Berlin Health stream. CDL’s rigorous, objectives-based mentoring aligns perfectly with our mission: to #BuildSomethingMassive by unlocking the full potential of CAR T-cell therapy in solid tumours. #ImmunoKey #CDLHealth #CellTherapy #CAR_T #Biotech #OvarianCancer #SolidTumours #VentureScience #InnovationInHealth

We’re thrilled to share that ImmunoKey has been awarded a $225,000 ScaleReady G-Rex® Grant to support the development of our CAR T-cell manufacturing process. This grant marks a significant milestone in our journey to deliver scalable, clinically meaningful CAR T-cell therapies for solid tumours. The funding will help de-risk key aspects of our process development as we progress toward preclinical proof-of-concept. A huge thank you to Andrew Scheffler and ScaleReady for recognising the potential of the CARKey™ platform. We’re excited to take this next step in building a robust, scalable platform for next-generation cell therapy. Read the press release here: https://lnkd.in/eAKYkJAH #CellTherapy #CART #SolidTumours #ImmunoKey #Manufacturing #BiotechInnovation #CARKeyPlatform #ScaleReadyGrant

Leyuan Bao, our Director of Research, has been invited to speak at CGT China Innovation Summit this September in Guangzhou, China! With global leaders in cell and gene therapy converging, we’re proud to represent UK innovation and share our ground breaking work on the CARKey™ platform, designed to overcome key barriers in CAR T-cell therapy for solid tumours. #CellTherapy #CARKey #ImmunoKey #CGTInnovation #BiotechNews #CGTechX #SolidTumours #CAR_T #OvarianCancer #ImmunoOncology